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Background: HCV affects 185 million people worldwide and leads to death and morbidities. HCV has
a high genetic diversity and is classiﬁed into seven genotypes and 67 subtypes. Novel anti-HCV drugs
(Direct-Acting-Antivirals) eligibility, resistance and cure rates depend on HCV geno/subtype (GT).
Objectives: Analysis of epidemiological information and viral GT from patients undergoing viral genotyp-
ing in 2011–2015.
Study design: Anonymized information from 52 centers was analyzed retrospectively.
Results:37,839sampleswere included in the study.Weshowthat theGTdistribution is similar throughout
Western European countries, with some local differences. Here GTs 1 and 2 prevalences are lower and
of GT4 higher than in all previous reports. Israel has a unique GT pattern and in South Russia the GT
proportions are more similar to Asia. GTs 5 and 6 were detected in very low proportions. Three cases of
the recombinant genotype P were reported in Munich (Germany).
In addition, we observed that GT proportion was dependant on patientsı´ gender, age and transmission
route: GTs 1b and 2 were signiﬁcantly more common in female, older, nosocomially-infected patients,
while GTs 1a, 3 and 4 were more frequent in male, younger patients infected by tattooing, drug consume,
and/or sexual practices. In infections acquired by drug consume, GTs 1a (35.0%) and 3 (28.1%) prevailed.
In infections related to sexual practices lower proportion of GT3 (14.0%) and higher of GT4 (20.2%) were
detected. GT4 was mostly abundant in MSM (29.6%). HIV coinfection was signiﬁcantly associated with
higher proportions GTs 1a and 4 (42.5% and 19.3%, respectively).
Conclusion: Genotype prevalence evolves and correlates to epidemiological factors. Continuous surveil-
lance is necessary to better assess hepatitis C infection in Europe and to take appropriate actions.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).. BackgroundHepatitis C virus (HCV) infects >185 million infections world-
ide, though occult infection may increase this number up to
0–30% [1]. Persistent HCV infection is associated with the devel-
∗ Corresponding author at: Institute of Virology, University of Cologne, Fürst-
ückler Str. 56, 50935 Cologne, Germany.
E-mail address: Rolf.kaiser@uk-koeln.de (R. Kaiser).
1 Names are listed at the end of the manuscript as HCV EuResist Study group.
ttp://dx.doi.org/10.1016/j.jcv.2016.05.010
386-6532/© 2016 The Authors. Published by Elsevier B.V. This is an open access article
/).opment of liver cirrhosis, liver failure or hepatocellular carcinoma,
and is the most common indication for liver transplantation.
HCV is a single stranded RNA virus belonging to the family Fla-
viviridae. HCV displays a high genetic diversity due to the high
mutation rate of the viral polymerase and the high turnover of the
virus.Viral variants are classiﬁed into sevengenotypes (named1–7)
and then further into at least 67 subtypes, (labelled as a, b, c, etc.)
[2].
HCV genotyping is performed by in-house sequencing followed
by phylogenetic analysis or use of internet-based genotyping tools
such as geno2pheno[HCV] (http://hcv.geno2pheno.org/index.php),
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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Table 1
Data overview.
Number and percentage of samples
Year of testing
2011 8301 (21.9%)
2012 7939 (20.9%)
2013 8410 (22.2%)
2014 8761 (23.1%)
2015 4533 (12.0%)
Genotype
GT1* 3860 (10.2%)
GT1a 9910 (26.2%)
GT1b 10832 (28.6%)
GT2 1952 (5.2%)
GT3 7754 (20.5%)
GT4 3415 (9.0%)
GT5 70 (0.2%)
GT6 36 (0.1%)
non-1, 2 or 3** 10 (0.0%)
Gender
M 20282 (53.6%)
F 9279 (24.5%)
unknown 8278 (21.9%)
transmission route/risk group
parenteral 2282 (9.9%)
vertical 13 (0%)
nosocomial 442 (2.0%)
tattoo/piercing 93 (0.5%)
IVDA*** 1231 (5.8%)
sexual 257 (0.9%)
unknown 34685 (91.7%)
age at testing
≥65 4496 (11.9%)
64–55 6663 (17.6%)
54–45 10423 (27.5%)
44–35 6034 (15.9%)
34–25 2209 (5.8%)
24–15 307 (0.8%)
≤14 78 (0.2%)
unknown 7629 (20.2%)
coinfections
HIV+ 2095 (5.5%)
HIV− 1311 (3.5%)
HIV unknown 34433 (91.0%)
HBV+ 1314 (3.5%)
HBV− 9325 (24.6%)
HBV unknown 27200 (71.9%)
* GT1 comprises genotype 1 samples not classiﬁed as 1a or 1b.
**V. Kartashev et al. / Journal o
r with commercial tests [3–7]. In spite of small differences in
he geno/subtype (GT) results among methods, the use of all these
ethods for clinical purposes has been extensively validated.
The licensing of the ﬁrst Direct-Acting-Antivirals (DAAs) tar-
eting HCV proteins has signiﬁcantly increased the cure rates [8].
owever HCV eradication by therapy implementation is hampered
ot only by high DAA-therapy costs but also by its genotype-
ependent implementation and success rates.
In spite of this critical role in HCV therapy, data on global
CV GT-distribution are limited. Most epidemiological studies are
estricted to regional level. Recent supranational works are meta-
nalyzes based in overlapping datasets and cover no or very few
pidemiological factors [9–13].
. Objectives
In this work we aimed to gain large-scale knowledge on GT dis-
ribution based on current data from centers routinely diagnosing
nd treatingHCV-infectedpatients.Additionally,we linked theHCV
enotype distribution to epidemiological parameters.
. Study design
.1. Study design
A list of the clinical sites providing samples and their geno-
yping methods are provided in Supplementary Table 1. Sample
nclusion criteria were: successful genotyping performed in the
ears 2011–2015 and report of genotyping method. Only one sam-
le per patient was included in the analysis. If available, additional
nformation was collected: patientsı´ year of birth or age at testing,
CV transmission route/risk group, and Human Immunodeﬁciency
irus (HIV)- or Hepatitis B virus (HBV)-coinfections. Markers for
resent or past HBV infection were HBs-antigen and/or anti-HBc.
atawere anonymized at the origin and then sent to the University
f Cologne for analysis and storage in the Arevir database.
.2. Statistical analysis
We used a log-linear model to analyze multivariate depend-
ncies between variables. In a ﬁrst analysis the GT was used as
he dependent variable and country, gender, date of birth, HIV-
oinfection, HBV-coinfection, and transmission route/risk group as
ndependent variables. Performance of the log-linear model was
valuatedbyp-values computed fromtheChi-squareddistribution,
sing the residual degrees of freedom and deviance of the model.
odel variates were selected based on the changes in degree of
reedom and deviance resulting from adding multivariate terms to
he model. Only terms with a p-value below 0.05 were retained.
e used Bonferroni correction to adjust the z-critical values for
igniﬁcance according to the size of the confusion table.We consid-
red three different p-values reﬂecting signiﬁcant (p≤0.05), very
igniﬁcant (p≤0.01), and highly signiﬁcant (p≤0.001) residuals.
For the multivariate dependency analysis, all models included
he genotype as a variable, since our main objective was the study
f genotype-dependent associations. Associations between year of
irth and country were not considered due to the intensity of the
ssociated computations.
. ResultsWe collected 37,839 genotypes from 52 centers from Austria,
elgium, Germany, Israel, Italy, Luxembourg, Portugal, Russia,
pain, and the UK, comprising. Raw and statistical data are sum-Three samples of GT-P were detected in Munich and seven samples of GT non-1,
-2 or -3 in Rostov on the Don.
*** Intravenous drug abusers.
marized in Supplementary Tables 1–3. Baseline characteristics are
shown in Table 1.
4.1. Geographic distribution of geno/subtypes
The overall proportion of GTs is shown in Fig. 1. The most preva-
lent was GT1, followed by GT3 and GT4. Three samples classiﬁed
as the recombinant genotype-P were identiﬁed in Munich. Some
geographic variations in GT proportions were observed (Table 2).
Geographic differences in the proportion of genotypes 1, 1a, and 1b
might be the result of differences in the speciﬁcity of genotype test-
ing rather than actual differences in the proportions. For example,
nearly 30% (51/174) of GT1 measurements from Luxembourg did
not differentiate between genotype 1a and 1b, while this was only
the case for less than 4% (60/1773) measurements from Portugal.
4.2. Distribution of geno/subtypes related to date of testing and
gender
The number of samples and GT proportion per year of testing
was homogeneous (Table 3). For 29,561 (78.1%) of the samples gen-
84 V. Kartashev et al. / Journal of Clinical Virology 81 (2016) 82–89
Fig. 1. geno/subtype distribution in the dataset.
GT1 in the pie graph corresponds to all samples classiﬁed as GT1.
(*)GT1 in the bar corresponds to all samples not classiﬁed as 1a or 1b.
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ier was reported, whereof 20,282 (68.6%) corresponded to male
atients and 9279 (31.4%) to females. GT distribution depended on
ender: GTs 1b and 2 were more prevalent in females, while GTs
a, 3, and 4 were more frequent in males.
.3. Distribution of geno/subtypes related to patients´ı age
The year of birth/age at testing was known for 31,150 (82.3%)
atients. GT distribution was highly dependent on patientsı´ age
r date of birth (Table 4), and the pattern was similar in all cen-
ers. GT1b associated with births not later than 1958 and GT2 with
atients born before 1954. We observed a highly signiﬁcant asso-
iation of GT1a in patients born between 1958–1974, and a less
igniﬁcant association in individuals born between 1974 and 1980.
he proportion of GT3 infections increased signiﬁcantly in patients
ith birth up to 1967. GT4 associated with patients born between
962 and 1974.
.4. Distribution of geno/subtypes related to coinfections with
BV/HIV
HBV-status was reported for 10,705 (28.3%) of the patients,
hereof 1320 were positive for HBV markers of infection (Table 4).
CV GT distribution was independent of HBV coinfection.
HIV-status was known for 13,622 patients, with 2412 (17.7%)
IV-positive and 11,210 (82.3%) not-infected patients. In HIV-
nfected patients, the proportion of GTs 1a and 4 infections was
igniﬁcantly higher compared to HIV-negative patients (42.5% vs.
0.6% and 19.3% vs. 9.6%, respectively). This effect was observed in
ll countries.
The total prevalence of GT3-infection was similar in both HIV-
nfected and HIV-negative groups.4.5. Distribution of geno/subtypes related to route of transmission
Data for HCV transmission route/risk group was available in
19 centers, and for 2547 patients, whereof 1525 patients reported
more than one possible transmission/risk group (Table 4). For 606
patients transmission was labelled as “unknown” and for 34,686
individuals no transmission/risk group was available.
Parenteral transmission of HCV represented the main known
mechanism of viral spread (2283 cases) and revealed a GT distribu-
tion very similar to the general pattern.
442 patients infected nosocomially and exhibited a different
genotype distribution, with a signiﬁcant majority of GT1b infec-
tions and fewer GTs 1a, 3, and 4.
56 infections occurred through tattoo/piercing, 1194 through
drug consume (IVDA) and for 37 cases both routes were reported.
For the tattoo/piercing risk group, the only association found was
with GT1b. Drug use signiﬁcantly correlated with a higher abun-
dance ofGTs 1a, 3, and4,whileGTs 1b and2weremoreuncommon.
Transmission in the context of sexual practices occurred in 257
patients,whereof 135were speciﬁcallyMSM.Weobservednoasso-
ciation between speciﬁc GT and transmissions in the context of
sexual practices. However, for MSM with sexual-associated trans-
mission, GT1a (57.0%) andGT4 (29.6%)were present in signiﬁcantly
higher proportions, while GTs 1b and 3 were rarely detected.
4.6. Multivariate dependency analysis
We created eight models to analyze the interdependence of
the variables (Supplementary Table 3). These models conﬁrmed
that the main transmission route was age-dependent: nosoco-
mial infections were signiﬁcantly more common in females, older
patients (born 1900–1954); drug use and MSM were signiﬁcantly
more common in middle-age male patients (born 1964–1974 and
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Table 2
Geno/subtype distribution by country.
Country N GT1* GT1a GT1b GT2 GT3 GT4 GT5 GT6 non−1, 2,
or 3**
Austria 447 23
(5.1%)
[+++]
122
(27.3%)
176
(39.4%)
17
(3.8%)
[−]
87
(19.5%)
21
(4.7%)
[−]
0
(0%)
1
(0.2%)
0
(0%)
Belgium 781 0
(0%)
153
(19.6%)
[−−−]
292
(37.4%)
[+++]
58
(7.4%)
[+++]
178
(22.8%)
77
(9.9%)
23
(2.9%)
[+++]
0
(0%)
0
(0%)
Germany 8332 165
(1.9%)
[−−−]
2989
(35.9%)
[+++]
2550
(30.6%)
[+]
336
(4.0%)
1710
(20.6%)
[++]
538
(6.5%)
[−−−]
18
(0.2%)
23
(0.3%)
[+++]
3
(0%)
Israel 84 0
(0%)
17
(20.2%)
66
(78.6%)
[+++]
0
(0%)
0
(0%)
1
(1.2%)
0
(0%)
0
(0%)
0
(0%)
Italy 2592 73
(2.8%)
[−−−]
567
(21.8%)
[−−−]
970
(37.4%)
[+++]
396
(15.4%)
[+++]
386
(14.9%)
[−−−]
198
(7.6%)
[−−]
2
(0.1%)
0
(0%)
0
(0%)
Luxembourg 293 51
(17.4%)
[+++]
78
(26.6%)
45
(15.4%)
[−−−]
9
(3.1%)
93
(31.7%)
[+++]
16
(5.5%)
0
(0%)
1
(0.3%)
0
(0%)
Portugal 2892 60
(2.1%)
[−−−]
1267
(43.8%)
[+++]
446
(15.4%)
[−−−]
44
(1.5%)
[−−−]
743
(25.7%)
[+++]
326
(11.3%)
5
(0.2%)
1
(0%)
0
(0%)
Russia 4085 982
(24.0%)
289
(7.1%)
849
(20.8%)
[−]
576
(14.1%)
[+++]
1382
(33.8%)
0
(0%)
0
(0%)
0
(0%)
7
(0.2%)
[+++]
Spain 17175 2467
(14.4%)
[+++]
3973
(23.1%)
[−−−]
5254
(30.6%)
453
(2.6%)
[−−−]
2885
(16.8%)
[−−−]
2119
(12.4%)
[+++]
20
(0.1%)
4
(0%)
[−−−]
0
(0%)
UK 1158 39
(3.4%)
[+++]
455
(39.3%)
[−−−]
184
(15.9%)
63
(5.4%)
[+++]
290
(25.0%)
119
(10.3%)
2
(0.2%)
[++]
6
(0.5%)
0
(0%)
The total number, percentage (in brackets), and statistical signiﬁcance (in square brackets) are shown. We considered three levels of signiﬁcance: signiﬁcant (p≤0.05, +
or −), very signiﬁcant (p≤0.01, ++ or −−), and highly signiﬁcant (p≤0.001, +++ or −−−), where “+” signs are used for prevalence above the expected value and “−” for
underrepresentation.
*
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** Three samples of GT-P were detected in Munich and seven samples of GT non-1
974–1980, respectively); and infection through tattooing/piercing
as signiﬁcantly increased in male younger patients born after
980.
HIV-coinfection was more prevalent in Spanish and British
atients, but infrequent for Germans, Italians, and Portuguese. It
as also overrepresented in MSM.
Country-speciﬁc differences in GT distribution were found for
IV-positive patients in Germany: GT4; Italy: GT1a; Spain: GT1a
nd GT4.
. Discussion
HCV coinfection is frequent in HIV-infected patients. HIV/HCV
oinfection was diagnosed in 18% of our cases where a HIV test had
een performed, though HIV/HCV coinfection rates ranging from
5% to 53% have been estimated by others [14,15]. HIV/HCV coin-
ection is associated with worse disease progression [16,17], and
lso challenges both HCV and antiretroviral therapy due to strong
rug-drug interactions [18].
With the licensing of potent DAAs, the global public health com-
unity embraced the possibility of eradicating a virus without a
accine. However, we now know that some roadblocks stand in
he way, and one major obstruction is the genetic variability of
he virus. HCV is classiﬁed into seven genotypes and 87 subtypes.
urrently, GT is the only factor accounting for DAA eligibility. In
ddition, need for the adjuvants ribavirin or interferon, duration
f treatment, DAA-resistance (prevalence of baseline mutations,
evelopment under treatment and persistence after treatment), as
ell as cure rates still remain highly dependent on HCV genotype
nd subtype [19–24]. In spite of its relevance, the contemporaryr -3 in Rostov on the Don.
global distribution of genotypes is not fully characterized. A num-
ber of previous literature revisions have reported global prevalence
of HCV GTs [9–13]. They may have a biased GTs inclusion, such
as higher proportion of GT1, because of its higher susceptibility
to DAAs, or GTs more prevalent in the past (1b or 2a) since those
patients are in higher need of treatment, while GTs becoming more
prevalent in the very last years (GT4) may be underrepresented.
GT1 has been reported to account for the vast majority of HCV
infections in Western Europe, with prevalences ranging 75–90%
[9,12,25], and indeed only DAAs eligible for treatment of GT1
viruses have reached the market. In our study, GT1 accounted only
for 66% of the infections in Western Europe and Israel. We could
conﬁrm that the subtypes 1a/1b ratio was dependent on patient
age and transmission route [11,26–29].
GT3 is the second most prevalent GT in Western Europe in our
and other studies [9–13], representing 20% to 28% of the infec-
tions. It is also one of the most challenging GT for therapy, as only
sofosbuvir and daclatasvir are licensed for its treatment, and this
GT associated with faster rates of ﬁbrosis progression and higher
prevalence of severe steatosis and hepatocellular carcinoma. GT3
has been diagnosed more frequently in drug consumers in certain
areas [26,27]. Our Study has shown that this association occurs in
most West European countries.
GT2 has been considered the thirdmost frequent genotypewith
prevalences ranging from 8% to 11% [9,11–13]. However, GT2 was
more infrequent inourdataset: 4.5% in total or 4.1%whenexcluding
Russia. It signiﬁcantly associated to females, nosocomial infection
and was mostly detected in older patients. Higher proportions of
GT2 were only found in Russia, more in accordance to the Asian GT
distribution, and in Italy [30,31]. GT2c was probably introduced in
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Table 3
xxx.
N GT1* GT1a GT1b GT2 GT3 GT4 GT5 GT6 Non−1, −2,
or −3**
Year
2011 7971 1015
(12.7%)
1853
(23.2%)
2230
(28.0%)
383
(4.8%)
1713
(21.5%)
750
(9.4%)
18
(0.2%)
8
(0.1%)
0
(0%)
2012 7834 833
(10.6%)
1946
(24.8%)
2401
(30.6%)
339
(4.3%)
1550
(19.8%)
746
(9.5%)
12
(0.2%)
4
(0.1%)
3
(0%)
2013 8410 1027
(12.2%)
2112
(25.1%)
2254
(26.8%)
431
(5.1%)
1853
(22.0%)
710
(8.4%)
13
(0.2%)
9
(0.1%)
0
(0%)
2014 8665 861
(9.9%)
2399
(27.7%)
2366
(27.3%)
394
(4.5%)
1814
(20.9%)
794
(9.2%)
20
(0.2%)
13
(0.2%)
0
(0%)
2015 4533 223
(4.9%)
1359
(30%)
1464
(32.3%)
239
(5.3%)
824
(18.2%)
414
(9.1%)
7
(0.2%)
2
(0%)
0
(0%)
2010–2015*** 426 0
(0%)
5
(1.2%)
209
(49.1%)
46
(10.8%)
166
(39%)
0
(0%)
0
(0%)
0
(0%)
0
(0%)
gender
male 20282 1753
(8.7%)
[−−−]
6749
(33.3%)
[+++]
4489
(22.1%)
[−−−]
673
(3.3%)
[−−−]
4259
(21.0%)
[+++]
2298
(11.3%)
[+++]
36
(0.2%)
22
(0.1%)
3
(0.0%)
female 9279 1064
(11.5%)
[+++]
1839
(19.8%)
[−−−]
3694
(39.8%)
[+++]
584
(6.3%)
[+++]
1384
(14.9%)
[−−−]
673
(7.3%)
[−−−]
27
(0.3%)
14
(0.2%)
0
(0%)
unknown 8278 1142
(13.8%)
1086
(13.1%)
2741
(33.1%)
575
(6.9%)
2277
(27.5%)
443
(5.4%)
7
(0.1%)
0
(0%)
7
(0.1%)
The total number, percentage (in brackets), and statistical signiﬁcance (in square brackets) are shown. We considered three levels of signiﬁcance: signiﬁcant (p≤0.05, +
or −), very signiﬁcant (p≤0.01, ++ or −−), and highly signiﬁcant (p≤0.001, +++ or −−−), where “+” signs are used for prevalence above the expected value and “−” for
underrepresentation.
* GT1 comprises genotype 1 samples not classiﬁed as 1a or 1b.
** Three samples of GT-P were detected in Munich and seven samples of GT non-1, -2 or -3 in Rostov on the Don.
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taly as a result of populationmovements during Italian colonialism
t the end of the 19th century, and it did not spread there through
ntravenous drug use [32].
GT4 has been traditionally associated to Central Africa and
he Middle East, with a West European proportion of around
% [9,10,12], with the exception of Spain with a prevalence of
–11% [12,13,25]. Ourdata indicate thatGT4proportion inBelgium,
ortugal, and UK is similar to Spain, and in Italy and Germany is
bout 7%. Overall, the West Europe prevalence was calculated as
%. We observed that GT4 transmission is related to sexual prac-
ices, especially in MSM, and in HIV-coinfected patients [13,28].
detailed study by de Bruijne and colleagues has shown that
T4 infections may be the consequence of three concomitant pro-
esses: increase in immigration from Northern and Central Africa,
heuseofdrugs, and the introductionofGT4dviruses intoEuropean
etworks of MSM and injection drug users. This work identi-
ed three GT4 clusters in the current Dutch epidemiology: (i)
T4a-infected Egyptian immigrants; (ii) GT4d-infectedDutch IVDA
atients; and (iii)HIV-positiveMSMwithGT4d [33]. Further studies
t molecular level are required to clarify the origin of the increased
roportion of GT4 in other European countries.
GTs 5 and 6 were detected in extremely low frequencies and
o association with independent epidemiological parameters was
ound. However, new recombinant forms such as GT P, ﬁrst iso-
ated in St. Petersburg (Russia) [34], are being detected in Germany.
n this GT the 5′ region up to the ﬁrst part of NS2 corresponds to
he subtype 2k, while the rest of the genome corresponds to 1b.
resently, HCV genotyping does not take into consideration recom-
ination at all as most methods are based on ampliﬁcation of single
ubgenomic fragments [3–7]. Our genotype P samples were iden-
iﬁed by genotyping based on regions located in on the 5′ genomic
egions followed by resistance testing of the DAA-target proteins.
ur results suggest that recombinant genotypes we are unaware
f may be spreading. Their role in the HCV epidemiology and their
esponse to treatments is to date fully unexplored. Future studiesspeciﬁc year was reported.
are required to scrutiny the existence or spreading of recombinant
GTs. Should the existence of recombinants be demonstrated, the
HCV genotyping commercial kits and in-house protocols will have
to be improved.
Our study has detected signiﬁcant associations of GTs and epi-
demiological parameters using more than clinical 37,000 samples.
However, it also shows that epidemiological data collection outside
clinical studies is poor. Transmission route/risk group was docu-
mented only for 6.5% of the patients. Clear subtype classiﬁcation
was not available for 40% of the samples impeding a reliable sub-
type distribution analysis in GTs 2–6, and “unresolved” or “mixed”
infections (signals corresponding to more than one GT in commer-
cial kits) were not always clearly separated from double infections
(unmistakable co-existence of two ormoreHCV strains). Therefore,
additional studiesare required toanalyzewhetherourobservations
concur to other centers inWest Europe. Epidemiological studies are
important to identify the extent of current difﬁcult-to-treat collec-
tives such as GT3-infected or HIV co-infected patients in order to
optimize vaccine and drug design as well as therapy policies.
In summary, the currentHCVgenotypedistribution is a dynamic
process inﬂuenced by traditional genotype prevalence and evolv-
ing transmission trends. The early-nineties epidemics of GTs 1b
and 2a spread by nosocomial transmission have been replaced by
a scenario of GTs 1a, 3a and 4 where IVDA and high-risk sexual
practices are the main risk factor for HCV (and HIV) transmission
[29,35–37]. However, other issues may also shape epidemiology
within the next years. The role of past and current immigration,
increase in sex/drug consume-tourism, infections in homeless peo-
ple and prisoners, HCV re-infections rates in IVDA, generation of
new (recombinant) GTs, as well as selection of certain GTs by the
current DAAs should be clearly elucidated [25,33,34,38–41]. More
regional but very detailed studies have shown the importance of
accurate risk group assessment and viral subtype determination,
but furthermore the utility of sequencing/phylogenetic analysis for
deeper insights in the spread of HCV [22,29,32,33].
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Table 4
Geno/subtype distribution by age at testing, viral coinfection and transmission route/risk group.
N GT1* GT1a GT1b GT2 GT3 GT4 GT5 GT6 Non−1, −2,
or −3**
Age at testing
≥65 4910 584
(11.9%)
476
(9.7%)
2954
(60.2%)
463
(9.4%)
222
(4.5%)
165
(3.4%)
41
(0.8%)
5
(0.1%)
0
(0%)
64−55 6473 531
(8.2%)
1823
(28.2%)
2228
(34.4%)
311
(4.8%)
1065
(16.5%)
493
(7.6%)
11
(0.2%)
10
(0.2%)
1
(0%)
54−45 10922 852
(7.8%)
3805
(34.8%)
2170
(19.9%)
295
(2.7%)
2362
(21.6%)
1422
(13.0%)
8
(0.1%)
8
(0.1%)
0
(0%)
44−35 6165 584
(9.5%)
1994
(32.3%)
1145
(18.6%)
181
(2.9%)
1501
(24.3%)
747
(12.1%)
4
(0.1%)
7
(0.1%)
2
(0%)
34−25 2287 243
(10.6%)
701
(30.7%)
463
(20.2%)
61
(2.7%)
609
(26.6%)
203
(8.9%)
1
(0%)
6
(0.3%)
0
(0%)
24−15 316 48
(15.2%)
85
(26.9%)
68
(21.5%)
9
(2.8%)
77
(24.4%)
27
(8.5%)
2
(0.6%)
0
(0%)
0
(0%)
≤14 80 12.0
(15%)
21
(26.3%)
17
(21.3%)
3
(3.8%)
15
(18.8%)
11
(13.8%)
1
(1.3%)
0
(0%)
0
(0%)
unknown 6686 1105
(16.5%)
769
(11.5%)
1879
(28.1%)
509
(7.6%)
2069
(30.9%)
346
(5.2%)
2
(0%)
0
(0%)
7
(0.1%)
Viral coinfec-tions
HIV positive 2412 118
(4.9%)
[−−−]
1026
(42.5%)
[+++]
346
(14.3%)
[−−−]
41
(1.7%)
[−−−]
414
(17.2%)
465
(19.3%)
[+++]
0
(0%)
2
(0.1%)
0
(0%)
HIV negative 11210 2219
(19.8%)
[+++]
2308
(20.6%)
[−−−]
3103
(27.7%)
[+++]
421
(3.8%)
[+++]
2058
(18.4%)
1080
(9.6%)
[−−−]
15
(0.1%)
6
(0%)
1
(0%)
HIV unknown 24217 1622
(6.7%)
6340
(26.2%)
7475
(30.9%)
1370
(5.7%)
5448
(22.5%)
1869
(7.7%)
55
(0.2%)
28
(0.1%)
0
(0%)
HBV positive 1320 83
(6.3%)
[−−−]
416
(31.5%)
360
(27.3%)
44
(3.3%)
259
(19.6%)
152
(11.5%)
2
(0.2%)
4
(0.3%)
2
(0%)
HBV negative 9385 2000
(21.3%)
[+++]
2191
(23.3%)
2121
(22.6%)
360
(3.8%)
1688
(18.0%)
1003
(10.7%)
15
(0.2%)
7
(0.1%)
0
(0%)
HBV unknown 27134 1876
(6.9%)
7067
(26.0%)
8443
(31.1%)
1428
(5.3%)
5973
(22%)
2259
(8.3%)
53
(0.2%)
25
(0.1%)
10
(0.1%)
Transmission route/risk group
Parenteral 2283 215
(9.4%)
691
(30.3%)
513
(22.5%)
[−−−]
66
(2.9%)
[−]
526
(23.0%)
[++]
270
(11.8%)
2
(0.1%)
0
(0%)
0
(0%)
vertical 13 0
(0%)
3
(23.1%)
7
(53.8%)
0
(0%)
1
(7.7%)
2
(15.4%)
0
(0%)
0
(0%)
0
(0%)
nosocomial 442 62
(14.0%)
[+]
54
(12.2%)
[−−−]
239
(54.1%)
[+++]
24
(5.4%)
41
(9.3%)
[−−−]
21
(4.8%)
[−−]
1
(0.2%)
0
(0%)
0
(0%)
tattoo/piercing 93 15
(16.1%)
28
(30.1%)
12
(12.9%)
4
(4.3%)
[−]
28
(30.1%)
6
(6.5%)
0
(0%)
0
(0%)
0
(0%)
IVDA 1231 132
(10.7%)
431
(35.0%)
[+++]
130
(10.6%)
[−−−]
27
(2.2%)
[−−]
346
(28.1%)
[+++]
164
(13.3%)
[+++]
1
(0.1%)
0
(0%)
0
(0%)
sexual 257 15
(5.9%)
111
(43.2%)
36
(14.0%)
6
(2.3%)
36
(14.0%)
52
(20.2%)
0
(0%)
1
(0.4%)
0
(0%)
unknown 34685 3728
(10.7%)
[−]
8729
(25.2%)
[+++]
10154
(29.3%)
[−]
1680
(4.8%)
7238
(20.9%)
[−]
3043
(8.8%)
[+++]
68
(0.2%)
35
(0.1%)
0
(0%)
The total number, percentage (in brackets), and statistical signiﬁcance (in square brackets) are shown. We considered three levels of signiﬁcance: signiﬁcant (p≤0.05,
+or −), very signiﬁcant (p≤0.01, ++ or −−), and highly signiﬁcant (p≤0.001, +++ or −−−), where “+” signs are used for prevalence above the expected value and “−” for
u
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Cnderrepresentation.
* GT1 comprises genotype 1 samples not classiﬁed as 1a or 1b.
** Three samples of GT-P were detected in Munich and seven samples of GT non-1
This work is the ﬁrst attempt for the establishment of a labo-
atory network for real-time collection of European HCV data to
rovide reliable information about the current GT prevalence sit-
ation, and it is also a call to join efforts and encourage further
bservational studies of HCV GT prevalence at supra-national level
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